The following statement is being issued by Jonathan Schochor, Chairman, Plaintiffs’ Steering Committee, regarding Jane Doe No. 1, et. al. v. Johns Hopkins Hospital, et al., No. 24-C-13-001041.
If you were a patient of, or treated by Johns Hopkins Hospital gynecologist, Dr. Nikita Levy, you are a member of a mandatory settlement class action.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/65136-dr-nikita-levy-class-action-lawsuit-johns-hopkins-hospital-gynecology
Weill Cornell Medical College today opened the Belfer Research Building, a state-of-the-art facility that ushers in a new era at the institution for cutting-edge, translational science. The 18-story, $650 million building, made possible through the generosity of numerous donors, nearly doubles Weill Cornell’s existing research space and empowers scientists to rapidly translate groundbreaking discoveries into the most advanced patient care.
To view Multimedia News Release, go to http://www.multivu.com/mnr/65415-weill-cornell-medical-college-belfer-cancer-research-building-opening
The Preeclampsia Foundation, the nation’s only non-profit patient advocacy organization for preeclampsia and related hypertensive disorders of pregnancy, today announced the results of a recent nationwide Preeclampsia Awareness Survey of more than 1,500 expectant and new mothers. These findings are driving the Foundation’s strategies associated with National Preeclampsia Awareness Month.
To view the Multimedia News Release, go to: http://www.multivu.com/mnr/7171451-preeclampsia-foundation-awareness-survey-education-pregnancy-disorders
Research shows that patients who don’t consistently follow their regular medication regimen are at risk for death or hospitalization. During American Pharmacists Month in October, American Pharmacists Association (APhA) Foundation is launching the Align My Refills campaign to help patients and caregivers maintain their medication regimen with patient resources and the aid of their local pharmacist.
To view Multimedia News Release, go to: http://www.multivu.com/players/English/7337851-american-pharmacists-association-foundation-align-my-refills-campaign/
In response to the growing need for quality healthcare in Chicago, Northwestern Medicine is proud to announce the opening of a new, one-million square foot outpatient pavilion at 259 E. Erie St. The new pavilion opened on Oct. 13 in the heart of Northwestern Medicine’s downtown medical campus, home to Northwestern Memorial Hospital and Northwestern University Feinberg School of Medicine.
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7049451-northwestern-medicine-to-open-259-east-erie-patient-pavilion-in-october/
With gout incidence on the rise, an increasing number of medical professionals, across multiple fields of practice, will continue to be exposed to patients who suffer from gout and are seeking an accurate diagnosis and treatment. However, despite the availability of the “Guidelines for the Management of Gout” by the American College of Rheumatology (ACR), there are many inconsistencies in how gout is diagnosed, treated and discussed by medical professionals. Conflicting messages and treatment recommendations can contribute to confusion, and even lack of compliance, on behalf of the patient – particularly when gout is connected with comorbid conditions, such as kidney disease, heart disease or diabetes.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7362551-gout-uric-acid-education-society-guaes-roundtable-consensus-paper/
I am a dialysis patient, we lost over 10 people in 3 years at my dialysis clinic so I thought I would make a farewell video to show I enjoyed my life in case I die prematurely
On the eve of World Cancer Day 2015, amidst the ongoing cost-of-cancer-care debate, PACE (Patient Access to Cancer care Excellence), a Lilly Oncology initiative, is launching the PACE Continuous Innovation Indicators™ (CII). CII is the first evidence-based, customizable online tool to review progress against cancer over time—initially covering 12 cancer types. The purpose of the tool is to inform public policy reforms and other efforts to accelerate continuous innovation against cancer.
“We have seen tremendous progress in cancer treatment and care during the past decades, and continuous innovation, with one discovery building on another, is responsible for most of it,” said John C. Lechleiter, Ph.D., Chairman, President, and Chief Executive Officer of Eli Lilly and Company (NYSE:LLY). “To keep the momentum going, we need policies that support continuous innovation, but first we need a deeper understanding of the innovations that have occurred, and where we need to be.”
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7419451-eli-lilly-oncology-pace/
Following years of trying to expand their family, Lisa and James Park of Raleigh, NC were named the winning family in Ferring Pharmaceuticals’ 2014 Heart to Heart Video Contest. This marks the tenth year Ferring has provided educational grants through patient contests, giving parents who have struggled with infertility the chance to win thousands of dollars for their child’s education by sharing their story.
Lisa and James’ rollercoaster journey to parenthood included multiple rounds of in vitro fertilization (IVF), intrauterine insemination (IUI) and a frozen embryo transfer. They hope that by sharing their story and video, they can help raise awareness about infertility and provide hope for others facing similar struggles. You can view Park family’s full video at www.hearttoheartcontest.com.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7444651-ferring-pharmaceuticals-heart-to-heart/
Today, the Pharmaceutical Research and Manufacturers of America (PhRMA) released a new report, “A Decade of Innovation in Rare Diseases,” to document the significant progress made in the last 10 years in understanding a broad range of rare diseases and translating this knowledge into groundbreaking therapies for a variety of patient populations.
The report illustrates that more than 230 new medicines to treat rare or “orphan” diseases were approved by the U.S. Food and Drug Administration (FDA) in the last decade, and there are currently more than 450 orphan drugs in development.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7350554-phrma-report-innovation-rare-diseases/
Chiasma, Inc., a U.S. privately–held biopharma company developing octreotide capsules for the orphan condition acromegaly, today announced two new studies presented at the 97th Endocrine Society (ENDO) Annual Meeting in San Diego, Calif. The studies provide additional data from Chiasma’s Phase III trial and new findings on the patient burden of current injection therapies.
“We now have data to help clinicians determine whether octreotide capsules, if approved, are likely to help their patient with acromegaly maintain response,” said Shlomo Melmed, M.D., senior vice president and dean, Cedars–Sinai Medical Center, Los Angeles and global study principal investigator. “Furthermore, the Phase III results show the safety and efficacy of octreotide capsules can be reliably determined within 12 weeks of initiating therapy.”
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7436451-endo-chiasma-clinical-data/
The American Society for Aesthetic Plastic Surgery (ASAPS), is hosting a panel discussion about the latest best practices and uses for injectables including the newest FDA-approved options at The Aesthetic Meeting today in Montreal, Quebec Canada.
The panel discussed the latest advances, including the ways various dermal fillers can be utilized to produce optimal results for targeted areas. There are thirteen FDA-approved dermal fillers on the market to-date, providing aesthetic plastic surgeons with the ability to customize anti-aging treatments to patients’ needs. “The filler choices are dictated by a patient’s unique aging pattern, the anatomical area to be treated and physiochemical properties,” explains ASAPS member, Dr. Z. Paul Lorenc.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7310753-asaps-facial-rejuvenation-injectables/
